Immunotherapy specialist Targovax reaches Phase IIa in operable pancreatic cancer with its TG01 immunotherapy. RAS specific immune responses were induced in all 6 patients in Phase I, and no substantial side effects were observed in the patients. The clinical trial has now expanded from Norway to two sites in the UK. Oslo Cancer Cluster […]
May 2015 is THE grand opening of Oslo Cancer Cluster Innovation Park and Oslo Cancer Cluster Incubator. Would you like to join us in the fight against cancer by being part of a power centre for developing innovative cancer treatment? Contact us now, and see what we may offer you as a tenant in the Innovation […]
May 2015 is THE grand opening of Oslo Cancer Cluster Innovation Park and Oslo Cancer Cluster Incubator. Would you like to join us in the fight against cancer by being part of a power centre for developing innovative cancer treatment? Contact us now, and see what we may offer you as a tenant in the Innovation […]
Oslo Cancer Cluster and French partner Cancer-Bio-Santé are joining forces with SwedenBio to offer the global Life Science industry the largest partnering conference in the Nordics – Nordic Life Science Days featuring the 6th European Cancer Cluster Partnering. Already now oncology biotechs, early stage companies and academics may submit an application for presenting at NLSDays-ECCP […]
